Does a Larger Putamen Mean Better Inhibition in Active Methamphetamine Dependence? A 37-Person MRI Study

Answer first: A study of 37 adults found a corrected right-putamen enlargement in 17 currently methamphetamine-dependent participants versus 20 controls, together with an inverse relation between putamen volume and computerized errors within the dependent cohort. It did not show a blood-drug threshold, proof of beneficial methamphetamine effects, or individualized impairment.

What is the answer in one paragraph?

In a structural MRI comparison of 17 adults actively using methamphetamine and 20 controls, the methamphetamine-dependent group had a larger right putamen by 7.52% after the investigators accounted for a head-size scaling factor. This regional difference was the only subcortical group contrast to remain statistically significant after the authors’ Bonferroni adjustment. Among methamphetamine-dependent participants who completed a separate response-inhibition task, larger right putamen volume correlated with fewer missed responses and fewer total errors. That observation does not establish that methamphetamine improved cognition, produced compensatory brain growth, or caused any individual to be less impaired. It is an association between anatomical MRI and task scores in a small, nonrandomized cohort, without chemically quantified methamphetamine in forensic blood specimens.

Which original experiment is being discussed?

The primary study is Reem K. Jan, Joanne C. Lin, Sylvester W. Miles, Rob R. Kydd and Bruce R. Russell, Striatal Volume Increases in Active Methamphetamine-Dependent Individuals and Correlation with Cognitive Performance, published in Brain Sciences in 2012. The complete original research report is available by its persistent identifier 10.3390/brainsci2040553. It examined structural brain anatomy and a separately administered computerized Go/No-go task. It was neither a controlled drug-administration experiment nor a validated driving test.

The distinction from studies of abstinent users matters: the investigators specifically recruited people reporting current methamphetamine use, confirmed eligibility by a qualitative urine drug test, and imaged them with a structural MRI scanner. The authors did not image these same people before the beginning of methamphetamine use, did not randomly assign participants to the drug, and did not follow the cohort longitudinally through recovery. Consequently, neither the direction nor the cause of the anatomical difference can be determined from this design.

How many independent people were enrolled?

The entire MRI comparison involved 37 independent people: 17 with a clinical diagnosis of methamphetamine dependence and 20 comparison volunteers without a history of drug addiction. The methamphetamine-dependent cohort included 12 men and five women; the controls included 13 men and seven women. Mean ages were 35.1 and 30.9 years, respectively, with an age comparison reported as nonsignificant (p = .095). Multiple MRI voxels, brain structures, repeated T1 acquisitions, computerized responses and statistical contrasts are not additional subjects.

For the correlation between right putamen volume and Go/No-go task scores, the experimental procedure expressly reports that one methamphetamine-dependent participant was excluded from the cognitive correlation because the testing was incomplete. That makes the complete-case behavioral correlation subset apparently 16 of the 17 imaging participants. The original Figure 2 caption nevertheless prints n = 17. The discrepancy should not be concealed by describing the 17 MRI subjects as 17 fully analyzed behavioral scores, and it is not resolved by assuming that the missing result was somehow recovered.

What substances and exposure histories were involved?

This was a naturalistic cohort, not a uniform laboratory dose. Within the 17 dependent participants, 12 reported smoking methamphetamine, three reported intravenous use and two reported both routes. The group reported an average 10.2 years of use, with a range of 2–25 years, and highly variable lifetime estimated use. These are histories supplied during interviews rather than measured assigned doses. An observed MRI contrast cannot be converted to a milligram exposure or concentration for an individual.

Most participants in the methamphetamine group also reported other substance use: 14 were regular nicotine users and 14 used cannabis, whereas none of the controls reported either category. Both exposure distributions differed markedly across groups. Alcohol-use category and sex did not show a statistically significant group difference in the source. The extreme imbalance in nicotine and cannabis is a central concern because any brain-structure association might involve methamphetamine, those co-exposures, unmeasured factors or a combination. Statistical adjustment for a head-size scaling factor does not erase that confounding.

Was methamphetamine actually quantified in human blood?

No. Investigators used a qualitative urine drug test for recent methamphetamine exposure, with a reported screening cutoff of 300 µg/L in urine. They also described health-related blood and urine testing, but the paper provides no paired numerical post-use or scan-time concentration of parent methamphetamine, amphetamine metabolite, or either optical isomer measured in a specifically documented legal venous whole-blood sample. No quantitative mass-spectrometric blood assay, calibration range, detection limit or exact elapsed time after last administration was reported for use in interpreting the MRI result.

A qualitative urine eligibility screen is not a measured concentration in circulating venous whole blood. It is also not the same specimen as separated plasma or serum. Nothing in this study authorizes equating a urine cutoff to a blood impairment threshold, converting a reported duration of use to a biological concentration, or treating health-screening blood collection as proof of forensic methamphetamine quantification.

What MRI data were collected and analyzed?

Each person underwent anatomical T1-weighted MRI at 1.5 tesla. Two acquisitions from the same scanning visit were combined to improve the anatomical estimates; they were not two drug-exposure experiments. The researchers assessed total brain compartments, then measured subcortical structures using a region-of-interest segmentation pipeline. They also performed an exploratory voxel-based morphometry analysis that evaluated localized grey-matter density in many brain locations.

Volumetric scaling was used to account for head size. That step helps one particular imaging comparison, but does not make the two recruitment groups exchangeable. Equally important, anatomical tissue volume is different from a functional MRI blood-oxygen signal, a positron-emission dopamine-receptor measurement, neuronal counting or direct histological evidence of inflammation. MRI can show a region appearing larger under a specified processing model without identifying the cellular material responsible.

Which regional volume difference survived the multiple-comparison adjustment?

The authors’ subcortical results found three nominally significant larger regions in the methamphetamine group: right putamen, left putamen and left nucleus accumbens. After Bonferroni adjustment, only the right putamen remained significant. Although the left putamen and left accumbens are scientifically interesting, using their unadjusted p values to declare three independently confirmed changes would exaggerate the evidence. Neither a caudate difference nor a globus pallidus difference reached the reported statistical criterion.

Percent differences describe averages of the source groups, not the probability that an individual has used methamphetamine or the percentage enlargement that any single scan must show. The printed F-statistic degrees of freedom are preserved as written rather than silently “corrected” from the participant count.

Were overall brain volumes different?

The researchers expressly reported no significant differences in total brain volume, total grey matter, white matter or cerebrospinal-fluid volume. That negative result is relevant: a local right-putamen difference was observed without evidence in this cohort for a broad shift in all major tissue compartments. A regional result does not mean the whole brain was enlarged.

Conversely, nonsignificant whole-brain contrasts are not proof of equivalence. A 37-person observational study can miss modest but real differences, and tissue segmentation estimates are not direct microscopic measurements. The correct answer is that the paper did not identify a statistically significant group contrast on those global outcomes under its own tests.

What did the Go/No-go task actually measure?

The computerized task instructed participants to respond to green “PRESS” prompts and withhold a response to red prompts. Stimuli appeared for 500 milliseconds at one-second spacing. The investigators recorded reaction time, false alarms or commission errors, missed responses or omission errors, and their combined total. The task is often used to study response inhibition, but it does not recreate the demands of driving a vehicle, assessing roadside sobriety, coordinating complex motor tasks or making a real-world legal decision.

Only the methamphetamine-dependent group received this cognitive test within this research protocol. Controls did not complete the same task for a direct between-group Go/No-go comparison. Instead, test scores were standardized against an external normative dataset and correlated with volumes within the methamphetamine group. A correlation of this kind cannot be presented as experimental proof that current users made fewer errors than controls, because that specific cross-group cognitive test was not performed.

How strongly did putamen volume correlate with errors?

Within the studied methamphetamine-dependent participants, larger right putamen volume was inversely associated with the standardized number of omission errors, and with the standardized total number of errors. The total-error coefficient was r = −.73, p = .001; the missed-response coefficient was r = −.71, p = .002. A negative correlation means the larger volumes tended to accompany fewer errors in the observed sample. It says nothing about the microscopic mechanism or whether enlarging a brain region would improve the same person’s performance.

The source’s figure caption prints n = 17 while its procedural description excludes one incompletely tested person. The conservative interpretation is to report the published correlation coefficients without inventing or silently repairing the exact analytic denominator. Neither coefficient is a validated forensic impairment, relapse-prediction or dose-to-response marker.

Why does the 17-person cohort not establish a cognitive benefit from methamphetamine?

The direction of the within-group correlation can tempt an appealing causal story: perhaps the brain enlarged its putamen to offset neurotoxicity and preserve inhibitory control. The authors discussed that hypothesis, but structural MRI alone cannot distinguish neural compensation from inflammation, reactive gliosis, differences that existed before methamphetamine use, vascular effects or unrelated selection factors. There was no randomized drug exposure and no pre-use scan that could identify an individual’s anatomical trajectory.

Even the task association is selective. Reduced omission and total error counts were the reported correlations, not a comprehensive demonstration of better executive control, working memory, reaction time, driving or judgment. A person’s performance could vary with sleep, withdrawal, practice, other substance exposure or motivation. The study’s original question is valuable precisely because it separates anatomical association from any assumption of drug-induced performance enhancement.

What did voxel-based morphometry find after correction?

An independent voxel-wise analysis showed uncorrected group clusters: less grey-matter density in portions of the left superior frontal and left precentral gyri, and greater signal in both putamina and the right superior lateral occipital region in the methamphetamine group. The authors report specific local magnitudes such as −23.4% and −26.9% in two frontal clusters and +14.1% in a right-putamen cluster, but these were findings at uncorrected statistical thresholds. None survived correction for the many locations tested.

That difference between a region-of-interest finding surviving the prespecified Bonferroni adjustment and a voxel-wise map that fails correction is essential. It is scientifically incorrect to quote the attractive colored brain clusters as independently replicated significant injury or enlargement. A spatial map is a visualization of one statistical model, not a direct photograph of an injury or a microscope measurement of dopamine neurons.

Did longer methamphetamine use predict a larger striatum?

No significant correlation was reported between subcortical regional volumes and either self-reported duration of methamphetamine use or estimated lifetime cumulative exposure. The exploratory within-group voxel-based analysis also found no significant link between grey-matter density and lifetime amount used. In this sample, reported years and estimated gram exposure did not supply a reliable quantitative dose-to-volume curve.

Those are genuine negative tests, not proof that duration or dose can never matter. The lifetime amount was estimated from participants’ recall, exposures varied over a broad interval, and the sample was small. It would be inappropriate to extrapolate from the lack of a correlation to a claim that a particular forensic blood concentration cannot affect a particular person, or to infer a fixed neurological stage from a disputed historical usage estimate.

Why are cannabis and tobacco important confounders?

The dependent and control samples differed in factors with potential brain correlates. Both cannabis use and regular nicotine use were reported by 14 of the 17 methamphetamine-dependent volunteers but by none of the 20 controls. Since these substances were not equally represented, statistical inference cannot isolate a pure methamphetamine effect merely by adjusting anatomical volume for head size. The authors expressly recognized that the effects of co-exposure could not be completely disentangled.

Group recruitment also did not balance all potentially relevant influences, such as nutritional history, prior conditions, lifestyle or detailed use patterns. The study’s finding remains a measured anatomical association within its selected groups, not a clean causal partition among methamphetamine, cannabis, nicotine and every confounder. This distinction is particularly important when a courtroom question asks whether one substance, in isolation, explains an identified person’s brain anatomy.

What is the distinction between urine confirmation and a blood toxicology opinion?

The reported urine screen served the study’s inclusion criteria for current use. It did not measure an exact methamphetamine mass in a legally collected venous whole-blood tube. A urine cutoff of 300 µg/L is a different reporting decision and biological matrix from ng/mL of methamphetamine in whole blood, plasma or serum. No numerical conversion is validated by these data. Nor is a positive qualitative screen a verified chiral measurement distinguishing d-methamphetamine from l-methamphetamine.

A case-specific forensic analysis would need the actual specimen, draw time, collection container, storage conditions, method validation, calibration, quality control and identified analytes, then independent clinical and incident evidence. An anatomical MRI group result cannot supply any of those missing analytical records. It also cannot establish when a person last used a drug from a single qualitative eligibility screen.

Can structural MRI identify methamphetamine intoxication or impairment in a particular person?

No. The study addresses anatomical differences between already-selected groups, using a cross-sectional design. It never established a personal diagnostic classification rule, a sensitivity or specificity for acute drug intoxication, a quantitative whole-blood concentration response, or a direct measure of driving performance. Its Go/No-go correlation involved a subset of dependent participants and standardized computer-test performance, not a courtroom reconstruction of collision avoidance or situational awareness.

Finding a relatively large putamen on one person’s scan cannot tell the clinician whether that person has consumed methamphetamine recently, is experiencing effects at a particular time, or caused an incident. The distribution of MRI volumes overlaps between groups, and a region’s size is affected by normal variation, acquisition, segmentation, and possible confounders. Neither enlargement nor lack of enlargement settles an individual drug-use or impairment question.

What should a forensic report preserve from the study?

A technically disciplined report should preserve the original study design and denominator: 17 active methamphetamine-dependent people against 20 controls for the anatomy, plus a task-correlation subset affected by one incomplete test. It should distinguish the surviving right-putamen corrected group finding from the nominal left-sided and accumbens contrasts. The non-significant global and voxel-wise adjusted outcomes deserve equal attention, as do the confounding cannabis/nicotine distributions and absent quantitative drug measurements.

The authors’ compensatory-response explanation is a hypothesis and should be labeled as such. A responsible presentation can explain why there is an interesting positive association between MRI structure and errors without promoting that hypothesis to demonstrated neuroprotection, brain damage, courtroom impairment or treatment efficacy. The source is useful background science, not a validated diagnostic or legal individualization instrument.

How should readers interpret these findings alongside forensic testing practice?

The appropriate question is not simply whether a positive drug-history group has a bigger putamen, but what was actually collected, measured and compared. For additional context on why anatomic imaging and an eligibility urine screen cannot be substituted for a quantified blood sample, see the site’s published guide to biological matrices. For the separate question of properly identified and validated drug results, see confirmatory drug testing.

These contextual pages do not turn this particular experiment into a forensic laboratory validation study. The primary observation was a region-specific MRI association, with no chemically measured parent or metabolite concentrations supplied for legal whole-blood interpretation, and no actual driving or injury outcome. Scientific honesty requires preserving those boundaries even when a strong within-group correlation or compelling brain image makes a mechanistic narrative attractive.

Seven frequently asked questions

Original primary research source

Jan RK, Lin JC, Miles SW, Kydd RR, Russell BR (2012). Striatal Volume Increases in Active Methamphetamine-Dependent Individuals and Correlation with Cognitive Performance. Brain Sciences 2(4):553–572. Original DOI: 10.3390/brainsci2040553. Original research is descriptive, and no personal forensic conclusions are implied by this analysis.